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rs1800787.Abstract Background: Single nucleotide polymorphism (SNP) 148C/T which is located in b-
ﬁbrinogen gene (FGB) promoter has correlation with ﬁbrinogen levels; however, the association
of SNP 148C/T and ischemic stroke in young adult patients is contradictory.
Aim: To determine the association of SNP 148C/T in FGB promoter with plasma ﬁbrinogen
levels and ischemic stroke in young adults.
Subjects and methods: In this case-control study, SNP 148C/T among 107 ischemic stroke
patients and 94 controls were evaluated by PCR-RFLP with restriction enzyme HindIII and con-
ﬁrmed by DNA sequencing. Physical and neurological examinations, brain computed tomography,
plasma ﬁbrinogen levels and blood biochemistry tests were assessed within seven days after the
onset of symptoms. Genotype distributions and allele frequencies were analyzed by chi-squared test.
Results: This study found that the level of ﬁbrinogen was signiﬁcantly higher in ischemic stroke
group than control (419.2 mg/dL vs. 351.1 mg/dL, p 6 0.000) and the level of ﬁbrinogen associated
with ischemic stroke (OR, 2.28; 95%CI, 1.28–4.07, p= 0.005). Mutant genotypes (CT and TT) and
T allele had a signiﬁcant association with hyperﬁbrinogenemia (OR, 2.58; 95%CI, 1.39–4.76 and
OR, 1.6; 95%CI, 1.60–2.41, respectively) and ischemic stroke (OR, 2.46; 95%CI, 1.37–4.41 and
OR, 1.80; 95%CI 1.19–2.73, respectively). In addition, analysis adjusted for other risk factors found
that mutant genotypes correlated with hyperﬁbrinogenemia and ischemic stroke (OR, 2.27; 95%CI,
1.21–4.25 and OR, 2.16; 95%CI, 1.19–3.94, respectively).
12 I. Imran et al.Conclusion: There was a signiﬁcant association between SNP 148C/T and ﬁbrinogen levels, SNP
148C/T and ischemic stroke, and ﬁbrinogen levels and ischemic stroke.
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Elevated plasma ﬁbrinogen, known as hyperﬁbrinogenemia, is
a risk factor for cardiovascular diseases and stroke [1–4] and
assessment of the ﬁbrinogen level could help to prevent cardio-
vascular event [5]. In addition, elevated ﬁbrinogen predicts
future ischemic stroke [3] and long-term oral ﬁbrinogen-deplet-
ing therapy is beneﬁcial for secondary ischemic stroke preven-
tion [6]. Elevated plasma ﬁbrinogen causes impaired blood
coagulation state, increases blood viscosity, slows blood ﬂow,
and facilitates platelet aggregation and adhesion to endothelial
cells; therefore, it inﬂuences blood rheology and plays an
important role in atherosclerotic lesion formation that induces
cerebrovascular diseases [7].
Fibrinogen, which is a dimeric glycoprotein, consists of
three pairs of polypeptide chains: two Aa, Bb and c. These
six polypeptide chains construct a hexamer (AaBbc)2 that is
joined together with 29 disulﬁde bonds. Aa, Bb and c chains
are encoded by 3 different genes, alpha ﬁbrinogen gene
(FGA), beta ﬁbrinogen gene (FGB) and gamma ﬁbrinogen
gene (FGG), respectively. FGB, which is 8.2 kb long, contains
8 exons [8], and Bb synthesis is the limiting step in the produc-
tion of mature ﬁbrinogen [9]. As a consequence, single nucleo-
tide polymorphisms (SNPs) affecting Bb production would
inﬂuence plasma ﬁbrinogen levels.
Several SNPs in FGB that determine ﬁbrinogen levels have
been identiﬁed and one of the most extensively studied is SNP
148C/T (rs1800787) which is located in FGB promoter. Stud-
ies have conﬁrmed that SNP 148C/T had association with
ﬁbrinogen concentration [10,11]. However, the association of
SNP 148C/T and ischemic stroke in adult patients is contra-
dictory [10,12–14]. Therefore, the aim of this study was to
determine the association of SNP 148C/T in FGB promoter,
ﬁbrinogen levels and ischemic stroke among Indonesian young
adult patients.
2. Subjects and methods
2.1. Study setting
This study was a case-control study and the study participants
were acute ischemic stroke patients who came for treatment at
Dr. Hasan Sadikin Hospital, Bandung. Ischemic stroke diag-
nostic criteria based on American Stroke Association were
applied in this study [15]. The controls were all non-stroke
patients – low back pain, radiculopathy, epileptic and myopa-
thy cases – who were age-, sex-, and race-matched, without his-
tory of stroke, and not related to the patients. Patients aged
over 50 years, had a history of stroke, had sign and/or symp-
tom of infection, had autoimmune disease, obesity, and use
of oral anticoagulants were excluded. In both patient and con-
trol groups, demographic data and detailed information about
cardiovascular risk factors were collected. In all patients, braincomputed tomography scan was conducted within seven days
of ischemic stroke symptoms onset.
At the admission time, clinical signs and symptoms and neu-
rologic status were assessed and venous blood samples were
collected under strictly standardized conditions. Fibrinogen,
cholesterol, high-density and low-density lipoprotein, triglycer-
ide, fasting blood sugar, two-hour postprandial blood sugar,
and uric acid levels were determined in the blood samples.
Fibrinogen was measured as von Clauss principle [16] with
Fibri-Prest Automate (Diagnostica Stago, Inc.). For SNP
148C/T genotyping, all blood samples were examined using
polymerase chain reaction-restriction fragment length poly-
morphism (PCR-RFLP) and conﬁrmed by DNA sequencing.
This study was conducted with the approval of the Ethics
Committee of Medical Faculty, Padjadjaran University, Ban-
dung, Indonesia, No. 09/FKUP-RSHS/KEPK/Kep/EC/2006.
The subject recruitment and sample collection were done only
after obtaining written informed consent of the participants.
The work was carried out in accordance with The Code of Eth-
ics of the World Medical Association (Declaration of Helsinki)
for experiments involving humans.
2.2. DNA extraction and SNP 148C/T genotyping
DNA isolation and PCR-RFLP were carried out at Faculty of
Medicine, Padjadjaran University, Bandung, Indonesia and
DNA sequencing conﬁrmation was conducted in 1st BASE
Pte. Ltd. Laboratory, Singapore. Brieﬂy, 5 ml peripheral venous
blood samples were obtained from patients and controls. DNA
was extracted fromwhole blood using the salting-out method as
described previously [17]. Genotyping was carried out as
described in previous report [12]. Forward primer was 50-
CCTAACTTCCCATCATTTTGTCCAATTAA-30, and
reverse was: 50-TGTCGTTGACACCTTGGGA CTTAAC-
TAG-30. Ampliﬁcation was performed with 36 cycles (denatur-
ation at 95 C for 15 s, annealing at 53 C for 45 s, extension at
72 C for 30 s) in the 200 lmol/L deoxynucleotide triphosphate,
2.5 mmol/L 1-1 magnesium chloride, and 0.15 units of Taq
DNA polymerase. RFLP was performed by digestion of 10 lL
of PCR product (362 bp) with 10 lL of HindIII restriction
enzyme for 24 h. Normally, HindIII cut DNA segments into
two fragments with a length of 264 bp and 98 bp.Digested prod-
ucts were electrophoresed through ethidium bromide-stained
3% agarose gels. Furthermore, the ampliﬁed products, ten sam-
ples from each group, were conﬁrmed by DNA sequencing,
using an ABI PRISM BigDye Terminator Cycle Sequencing
Ready Reaction Kit and a 3730 DNA analyzer (Applied
Biosystems).
2.3. Statistical analysis
Risk factors of ischemic stroke between case and control
groups were analyzed with chi-squared test and Fisher’s exact
test or Student’s t-test as appropriate with data. Differences in
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cies between ischemic stroke cases and control groups were
analyzed with chi-squared test to assess the association of
SNP 148C/T with hyperﬁbrinogenemia and ischemic stroke.
Adjusted odd ratios of genotype and allele of SNP 148C/T
with hyperﬁbrinogenemia and ischemic stroke were calculated
by logistic regression models. Two-tailed test was used for all
signiﬁcant comparisons to evaluate a statistical p-value of
60.05 as signiﬁcant.
3. Results
3.1. Sample characteristics and ischemic stroke risk factors
A total of 201 participants, 107 cases (mean age was
42.2 ± 6.53 years old) and 94 controls (mean age was
40.8 ± 9.14 years old) were enrolled in this study. There was
no signiﬁcant difference for sex, age and smoking attitude
between case and control groups. Blood biochemistry features
and risk factors of ischemic stroke between case and control
groups are shown in Table 1. Ischemic stroke patients more
often had hypertension (p 6 0.001), diabetes (p 6 0.05), dyslipi-
demia (p 6 0.05) and hyperuricemia (p 6 0.05) compared to
controls. As expected, the level of ﬁbrinogen was higher in case
than the control group (419.2 ± 118.36 mg/dL vs.
351.1 ± 96.99 mg/dL, p< 0.001). In this study, ﬁbrinogen
level >375 mg/dL was used as cut off point of hyperﬁbrinoge-
nemia. By using this cut off point, 51.8% of cases had hyperﬁ-
brinogenemia and 34.4% of controls had hyperﬁbrinogenemia.Table 1 Sample characteristics and ischemic stroke risk factors bet
Characteristic Ischemic stroke n (%
Sex, mena 49 (45.8)
Average ageb 42.2 (±6.53)
Smokinga 46 (43.0)
Diabetes mellitusa 14 (13.1)
Fasting blood sugar (mean, mg/dL)b 109.3 (±49.62)
Two-hour PP sugar (mean, mg/dL)b 134.5 (±65.44)
Hypertensiona 75 (70.1)
Systolic blood pressure (mean, mm Hg)b 153.2 (±33.18)
Diastolic blood pressure (mean, mm Hg)b 92.6 (±15.98)
Hypercholesterolemiaa 43 (40.2)
Total cholesterol (mean, mg/dL)b 194.5 (±43.29)
High low-density lipoproteina 20 (18.7)
Low-density lipoprotein (mean, mg/dL)b 119.2 (±39.68)
Low high-density lipoproteina 77 (72.0)
High-density lipoprotein (mean, mg/dL)b 43.9 (±16.33)
Hypertriglyceridemiaa 35 (32.7)
Triglyceride (mean, mg/dL)b 139.1 (±56.39)
Hyperuricemiaa 11 (10.3)
Blood uric acid (mean, mg/dL)b 5.8 (±2.50)
Hyperﬁbrinogenemiaa 54 (51.8)
Serum ﬁbrinogen (mean, mg/dL)b 419.2 (±118.36)
PP: postprandial.
a Chi-squared test analysis.
b Student’s t-test analysis.
* Statistically signiﬁcant at 60.05.
** Statistically signiﬁcant at 60.001.Analysis found that there was a strong association between
hyperﬁbrinogenemia status and ischemic stroke (OR, 2.28;
95%CI, 1.28–4.07, p= 0.005).
3.2. Association of SNP 148C/T FGB and ﬁbrinogen levels
The SNP 148C/T was genotyped by PCR-RFLP with the
genotyping success rates of 95%–100% and repeatability
rates of 98%–100%. DNA sequencing was used to further
conﬁrm the genotypes for SNP 148C/T from both groups
(10% samples each group) with the concordance rates
between RFLP and DNA sequencing being 98–100%. The
location of SNP 148C/T is presented in Fig. 1A. The ampli-
ﬁed PCR products (362 bp) were digested with HindIII and
electrophoresed through 3% agarose gels. Two fragments of
264 and 98 bp were categorized as homozygous CC genotype
(normal genotype), whereas a 362 bp fragment was catego-
rized as homozygous TT genotype (homozygote mutant
genotype). Three fragments of 362, 264 and 98 bp were cate-
gorized as heterozygous CT (heterozygous mutant genotype)
(Fig. 1B).
Among cases and controls, the level of ﬁbrinogen in
mutant genotypes (CT and TT) was signiﬁcantly higher than
normal genotype (CC) (404.5 ± 123.90 mg/dL vs.
359.1 ± 88.72 mg/dL, p= 0.006) (Table 2). By using
375 mg/dL as cut off point hyperﬁbrinogenemia, there were
83 hyperﬁbrinogenemia and 118 normal ﬁbrinogen level
among patients and controls. On further analysis, this study
found that hyperﬁbrinogenemia had a signiﬁcant associationween case (n= 107) and control (n= 94) groups.
) Control n (%) OR (95%CI) p
37 (39.4) 1.3 (0.72–2.31) 0.219
36.8 (±9.14) 0.076
31 (33.0) 1.5 (0.91–2.73) 0.095
5 (5.3) 2.6 (0.91–7.70) 0.049*
95.6 (±33.13) 0.025*
117.8 (±46.26) 0.041*
14 (14.9) 13.4 (6.61–27.4) 0.000**
122.4 (±13.91) 0.000**
79.7 (±7.97) 0.000**
23 (24.5) 2.1 (1.13–3.82) 0.013*
192.7 (±39.99) 0.765
8 (8.5) 2.4 (1.04–5.92) 0.029*
98.6 (±46.28) 0.001*
34 (36.2) 4.5 (2.50–8.23) 0.000**
59.2 (±14.19) 0.000**
9 (9.6) 4.6 (2.11–10.21) 0.000**
115.6 (±72.21) 0.010*
1 (1.1) 10.7 (1.33–84.26) 0.005*
4.8 (±0.87) 0.000**
29 (34.3) 2.28 (1.28–4.07) 0.005*
351.1 (±96.99) 0.000**
Figure 1 (A) Localization of SNP 148C/T FGB in a schematic map of the ﬁbrinogen gene cluster. (B) The PCR-RFLP product
electrophoresis of SNP148C/T FGB. Description: Lane 1: DNAmarker ladder 100, Lane 2: uncut PCR-RFLP product of 362 bp, Lanes 3
and 7: CC genotype, and Lanes 4–6: CT genotype. Homozygous TT genotype characterized with a 362 bp fragment (not present in (B)).
14 I. Imran et al.with mutant genotype (OR, 2.58; 95%CI, 1.39–4.76) and T
allele (OR, 1.6; 95%CI, 1.60–2.41) (Table 3). Furthermore,
logistic regression analysis (adjusted for sex, age, smoking sta-
tus, diabetes mellitus, hypertension, dyslipidemia and blood
uric acid level) found that hyperﬁbrinogenemia was correlated
signiﬁcantly with mutant genotype (OR, 2.27; 95%CI, 1.21–
4.24) (Table 3).
3.3. Association of SNP 148C/T FGB and ischemic stroke
There were signiﬁcant differences in the genotype distributions
and allele frequencies between case and control groups
(Table 4). In addition, there was a strong association between
mutant genotypes (CT and TT) and ischemic stroke (OR, 2.46;
95%CI, 1.37–4.41) and between mutant allele (T allele) and
ischemic stroke (OR, 1.80; 95%CI, 1.19–2.73). Furthermore,
logistic regression analysis found that mutant genotype and
mutant allele were signiﬁcantly correlated with ischemic stroke(OR, 2.16; 95%CI, 1.19–3.94, and OR, 1.68; 95%CI, 1.10–2.57
respectively) (Table 4).4. Discussion
Our previous studies have revealed that SNPs in speciﬁc genes
inﬂuence the human susceptibility either to infectious diseases
[18–21] or other condition related infections [22]. In this study
we tried to determine the association between SNP 148C/T
and hyperﬁbrinogenemia and ischemic stroke. The genetic
inﬂuence on FGB has been extensively studied, because Bb
synthesis is the limiting step in the production of mature ﬁbrin-
ogen [9]. One of the SNPs present in FGB, 148C/T, is located
in FGB promoter (see Fig. 1A). This study found that the lev-
els of ﬁbrinogen from persons who had mutant T allele (CT
and TT) in 148C/T were signiﬁcantly higher than persons
who had normal allele (C allele). Therefore, this study con-
Table 2 The association of SNP 148C/T and ﬁbrinogen
levels among ischemic stroke and control groups (n= 201).
Genotype and allele Mean of ﬁbrinogen level (mg/dL) p
Genotype 0.014*
CC 359.1 (±139.22)
CT 408.5 (±121.24)
TT 382.1 (±88.72)
Dominant model 0.006*
CC 359.1 (±88.72)
CT + TT 404.5 (±123.90)
Recessive model
CC+ CT 387.9 (±111.29) 0.833
TT 382.1 (±139.22)
Allele
C 379.4 (±111.00) 0.061
T 401.6 (±123.20)
* Statistically signiﬁcant at 60.05.
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ogen levels (hyperﬁbrinogenemia) as mentioned previously
[10,11,23,24]. Meta-analysis study also found that ﬁbrinogen
levels of allele T carrier (TT and CT) in 148C/T were higher
than C allele among ischemic stroke patients in Han Chinese
population [25]. In addition, in the general population, the
level of plasma ﬁbrinogen is signiﬁcantly higher in the groups
of genotypes 148C/T and TT than CC [13].
One of the possible reasons is because SNP 148C/T is
close to the responsive elements of interleukin-6 (IL-6), the reg-
ulating element of the activating repression of ﬁbrinogen gene
transcription [7] (Fig. 1A). Sequences responsive element of
IL-6 including CCAAT box/enhancer-binding protein (C/
EBP)-binding site, hepatocyte nuclear factor (HNF) and IL6-Table 3 The association of SNP 148C/T and hyperﬁbrinogenemi
Genotype and allele Hyperﬁbrinogenemia
Yes (n%) No
Genotype
CC 22 (26.5) 55
CT 53 (63.9) 52
TT 8 (9.6) 11
Dominant model
CC 22 (25.0) 55
CT + TT 61 (75.0) 63
Recessive model
CC+ CT 75 (90.4) 107
TT 8 (9.6) 11
Allele
C 96 (57.8) 162
T 70 (42.2) 74
Logistic regression modela
C vs. T
CC vs. CT + TT
**Statistically signiﬁcant at 60.001.
a Adjusted for sex, age, smoking status, diabetes mellitus, hypertension
* Statistically signiﬁcant at 60.05.responsive element (IL-6 RE), are present in FGB promoter
region [26]. Verschuur et al. [27] found that SNP 148C/T,
which is present between HNF-3-binding site and C/EBP-
binding site, inﬂuences ﬁbrinogen promoter activity in
response to IL6.
van Goor et al. [14] argue that a high level of ﬁbrinogen in
the acute phase of ischemic stroke probably represents an
acute phase response. They found that there were signiﬁcant
differences between ﬁbrinogen levels in patients and controls
during acute onset of ischemic stroke, but no difference after
three months of acute onset. Although, ﬁbrinogen levels might
reﬂect inﬂammatory process that is caused by ischemic stroke,
ﬁbrinogen levels might contribute directly to ischemic stroke
development because it contributes to generation and progres-
sion of atherosclerosis -inducing platelet aggregation, decreas-
ing blood viscosity and increasing endothelial cell injury- and
affects the stability and structure of the plaque [7,27].
The important role of SNP 148C/T also has been studied
related to other cardiovascular diseases. Previous study found
that the presence of the T allele has been associated with angio-
graphic severity of atherosclerosis in postmyocardial infarction
[28] and the TT genotype has been associated with carotid ath-
erosclerosis [29]. Furthermore, recent study from a meta-anal-
ysis including 15,055 subjects in Chinese population found that
there was a signiﬁcant association between SNP 148C/T and
coronary artery disease under allelic, recessive, dominant and
homozygous genetic models [30]. This study found that mutant
genotypes (CT and TT) and mutation allele (T) in SNP
148C/T had a signiﬁcant association with ischemic stroke.
This evidence suggests that the T allele is a risk factor for ische-
mic stroke at young age. A meta-analysis conducted in China,
showed that SNP 148C/T contributed to the vulnerability of
ischemic stroke in Han Chinese and allele T carrier increased
the risk of ischemic stroke about 32% compared with the wild
CC homozygote [25].a.
OR (95%CI) p
(n%)
- 0.012*
(46.6)
(44.1)
(9.3)
2.58 (1.39–4.76) 0.002*
(46.6)
(53.4)
1.04 (0.39–2.70) 0.562
(90.7)
(9.3)
1.60 (1.06–2.41) 0.017*
(68.6)
(31.4)
1.45 (0.95–2.21) 0.086
2.27 (1.21–4.25) 0.011*
, dyslipidemia and blood uric acid level.
Table 4 The association of SNP 148C/T and ischemic stroke.
Genotype and allele Ischemic stroke OR (95%CI) p
Yes (n%) No (n%)
Genotype - 0.012*
CC 31 (29.0) 46 (48.9)
CT 63 (58.9) 42 (44.7)
TT 13 (12.1) 6 (6.4)
Dominant model 2.46 (1.37–4.41) 0.002*
CC 31 (28.0) 46 (49.0)
CT + TT 76 (72.0) 48 (51.0)
Recessive model 2.03 (0.74–5.57) 0.124
CC+ CT 94 (87.9) 88 (93.6)
TT 13 (12.1) 6 (6.4)
Allele 1.80 (1.19–2.73) 0.004*
C 124 (57.9) 134 (71.3)
T 90 (42.1) 54 (28.7)
Logistic regression modela
C vs. T 1.68 (1.10–2.57) 0.017*
CC vs. CT + TT 2.16 (1.19–3.94) 0.012*
a Adjusted for sex, age, smoking status, diabetes mellitus, hypertension, dyslipidemia and blood uric acid level.
* Statistically signiﬁcant at 60.05.
16 I. Imran et al.A study found that there was no relationship between SNP
148C/T and ischemic stroke in their total sample, but in the
subgroup of smoking population the odd ratio of allele T carri-
ers to CC homozygotes reached 4.85 [30]. In addition, persons
with mutant genotype in SNP 148C/T (combined with other
gene polymorphisms) had an elevated incidence of ischemic
stroke and the incidence was increased with combination with
other risk factors such as smoking and alcohol consumption
[31]. It seems that interaction of SNP148C/T and environmen-
tal factors is important. However, other studies found that SNP
148C/T had no association with ischemic stroke [14] and other
cardiovascular events [12]. These differences might due to racial
differences as described previously [32].
Furthermore, this study found that ﬁbrinogen level was
associated with ischemic stroke in young age. Inﬂammatory
factors such as ﬁbrinogen are consistently associated with an
increased risk of cardiovascular diseases including stroke. Pre-
vious data revealed that ﬁbrinogen level was associated with
stroke [2,33–35] and increased ﬁbrinogen levels were associated
with poor outcome [33,36] and mortality of ischemic stroke
[34]. Levels of ﬁbrinogen were strongly associated with ische-
mic stroke severity in almost all studied populations [36]. In
addition, it is clear that modiﬁcation of prothrombotic factors
in ischemic stroke is beneﬁcial [37]. Therefore, if the elevation
of ﬁbrinogen is controlled by genetic factor; preventive efforts
to reduce or normalize plasma ﬁbrinogen levels might be
important to minimize ischemic stroke incidence in young
age adults.
There are several limitations of this study. This study did
not obtain prospective data examining the effect of SNP
148C/T on long-term clinical outcome. In addition, the
controls were patients who visited hospital with non-ische-
mic stroke; therefore this approach might cause hospital
control bias. Finally, this study did not measure the level
of ﬁbrinogen in convalescent phases; therefore, this study
was unable to answer debatable question whether ﬁbrinogenis a risk factor of ischemic stroke or merely a marker of
acute phase reactions.
5. Conclusion
This study found thatmutant genotypes (TT andCT) in148C/
T FGB had a signiﬁcant correlation with hyperﬁbrinogenemia
and ischemic stroke compared with normal genotype (CC),
and a high level of ﬁbrinogen was associated with ischemic
stroke in young adult patients. It seems that hyperﬁbrinogene-
mia is a predictor factor for ischemic stroke in young adults.Conﬂict of interest
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